Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEDOPI maintenance with or without pembrolizumab versus best supportive care in platinum-sensitive recurrent ovarian cancer
2020-004364-25Phase 2Active
- Sponsor
- Arcagy-Gineco
- Start
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in ovarian cancer comparing TEDOPI maintenance, TEDOPI plus pembrolizumab maintenance and Best supportive care (3 arms). Primary endpoint: Progression-free survival. Started Nov 2020; status: active.
02
Drugs
Tedopipembrolizumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2020-004364-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004364-25.